Big Pharma
5 September 2025 The UK pharma giant has opened a new front in its global litigation strategy involving Moderna, Pfizer, and BioNTech.
4 September 2025
28 August 2025
15 August 2025
Latest Features
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
More News
6 August 2025 With AI accelerating drug development, pharma companies must rethink how they protect models, data, and innovation, say Camille Terfve and Sean Jauss of Mewburn Ellis.
5 August 2025 A much-anticipated referral could upend the EPO’s controversial description amendment rule—and reshape European patent practice, as the Enlarged Board of Appeal prepares to weigh in on G 1/25.
4 August 2025 UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.
1 August 2025 German Federal Patent Court invalidates key patent for Xarelto | Bayer faces intensifying generic competition across Europe | Legal team highlights Germany’s crucial role in patent litigation and the importance of stopping early generic entry to protect market exclusivity.
31 July 2025 Settlement ends expectations of SCOTUS petition | Federal Circuit stipulates patents must explicitly claim the active ingredient of a drug to qualify for Orange Book listing | FTC backs Amneal, saying ‘improper listings’ stifle generic competition.
31 July 2025 The pharma manufacturer defeats an Italian hemp firm’s EU trademark bid | Claimed name could be confused for its blockbuster drug Xanax | EUIPO found strong market position and product overlap created risk of confusion.
29 July 2025 Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox